Ro 60-0175 fumarate

Pricing Availability Delivery Time Qty
Cat.No. 1854 - Ro 60-0175 fumarate | C11H12ClFN2.C4H4O4 | CAS No. 169675-09-6
Description: Potent, selective 5-HT2C agonist
Chemical Name: (αS)-6-Chloro-5-fluoro-α-methyl-1H-indole-1-ethanamine fumarate
Purity: ≥98% (HPLC)
Datasheet
Citations (7)
Literature

Biological Activity

Potent, selective 5-HT2 receptor agonist; shows selectivity for the 5-HT2C subtype (pKi values are 9, 7.5, 5.4, 5.2 and 5.6 for human 5-HT2C, 2A, 1A, 6 and 7 receptors respectively). Centrally active following oral or systemic administration in vivo.

Compound Libraries

Ro 60-0175 fumarate is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 342.75
Formula C11H12ClFN2.C4H4O4
Storage Desiccate at RT
Purity ≥98% (HPLC)
CAS Number 169675-09-6
PubChem ID 6446435
InChI Key CEPHEXXZGQBXGT-XZTIXWOLSA-N
Smiles O=C(O)/C=C/C(O)=O.FC1=C(Cl)C=C(N(C[C@H](C)N)C=C2)C2=C1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 6.86 20
water 1.71 5

Preparing Stock Solutions

The following data is based on the product molecular weight 342.75. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 2.92 mL 14.59 mL 29.18 mL
5 mM 0.58 mL 2.92 mL 5.84 mL
10 mM 0.29 mL 1.46 mL 2.92 mL
50 mM 0.06 mL 0.29 mL 0.58 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:
Safety Datasheet

References

References are publications that support the products' biological activity.

Damjanoska et al (2003) Neuroendocrine evidence that (S)-2-(chloro-5-fluoro-indol-l-yl)-1-methylethylamine fumarate (Ro 60-0175) is not a selective 5-hydroxytryptamine2C receptor agonist. J.Pharmacol.Exp.Ther. 304 1209 PMID: 12604698

Kennett et al (2000) Effects of Ro 60 0175, a 5-HT2C receptor agonist, in three animal models of anxiety. Eur.J.Pharmacol. 387 197 PMID: 10650160

Martin et al (1998) 5-HT2C receptor agonists: pharmacological characteristics and therapeutic potential. J.Pharmacol.Exp.Ther. 286 913 PMID: 9694950

Jensen et al (2013) Design, synthesis, and pharmacological characterization of N- and O-substituted 5,6,7,8-tetrahydro-4H-isoxazolo[4,5-d]azepin-3-ol analogues: novel 5-HT2A/5-HT2C receptor agonists with pro-cognitive J.Med.Chem. 56 1211 PMID: 23301527


If you know of a relevant reference for Ro 60-0175 fumarate, please let us know.

View Related Products by Target

View Related Products by Product Action

View all 5-HT2C Receptor Agonists

Keywords: Potent selective 5-HT2C agonists Serotonin Receptors Ro60-0175 5-HT2C Receptors

7 Citations for Ro 60-0175 fumarate

Citations are publications that use Tocris products. Selected citations for Ro 60-0175 fumarate include:

Martin et al (2015) 5-HT2C receptor desensitization moderates anxiety in 5-HTT deficient mice: from behavioral to cellular evidence. Synapse 18 PMID: 25522398

Kasper et al (2015) Serotonin-2C receptor agonists decrease potassium-stimulated GABA release in the nucleus accumbens. J Neurophysiol 69 78 PMID: 25382408

Martin et al (2014) Effect of genetic and pharmacological blockade of GABA receptors on the 5-HT2C receptor function during stress. J Neurochem 131 566 PMID: 25113583

Craige and Unterwald (2013) Serotonin (2C) receptor regulation of cocaine-induced conditioned place preference and locomotor sensitization. Behav Brain Res 238 206 PMID: 23103406

Manvich et al (2012) Effects of serotonin 2C receptor agonists on the behavioral and neurochemical effects of cocaine in squirrel monkeys. J Pharmacol Exp Ther 341 424 PMID: 22328576

Yu and Yamaguchi (2010) Endogenous serotonin acts on 5-HT2C-like receptors in key vocal areas of the brain stem to initiate vocalizations in Xenopus laevis. J Biol Chem 103 648 PMID: 19955293

Yu and Yamaguchi (2009) 5-HT2C-like receptors in the brain of Xenopus laevis initiate sex-typical fictive vocalizations. J Neurophysiol 102 752 PMID: 19474172


Do you know of a great paper that uses Ro 60-0175 fumarate from Tocris? If so please let us know.

Commented out for usability testing

Reviews

TODO: Add Reviews

Literature in this Area

GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
5-HT Receptors

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's

Parkinson's Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.

Pathways for Ro 60-0175 fumarate

Protocols

TODO: Add Protocols